Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

Forbes contributors publish independent expert analyses and insights. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. How does a venerable American brand known for creating the ...

David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

Jet fuel prices have surged since the Iran war started, prompting airlines to raise ticket prices. Travel gurus say booking flights with points or miles is best when cash prices are high. For those ...

The US federal government’s central energy information agency is planning to implement a mandatory nationwide survey of data centers focused on their energy use, according to a letter seen by WIRED.

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

If you’re a water resources student in Amarillo, you know the struggle: Texas watersheds often have incomplete streamflow ...

Seventeen wagons set up in Abilene to compete in this year's Texas Heritage Classic Chuckwagon Cook-off at the Taylor County Expo Center. Repeat Child Sex Offender Arrested Again in Tom Green County, ...

Wisconsin is becoming a popular location for data centers due to its climate, water access, and affordable land. The majority of a data center's water footprint comes from the offsite electricity ...

Attribution researches the influence of climate change on local weather and impacts. We issues alerts in many instances when the Climate Shift Index identifies a notable extreme weather event around ...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...